New IDWeek 2024 study reveals disparities in PrEP uptake across key U.S. populations. While overall PrEP usage has increased, ...

PrEP use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association.

In the last 30 years, HIV rates have gone down, in large part because of the game-changing prescription drug pre-exposure ...

Pre-exposure prophylaxis (PrEP ... indicating substantial growth in HIV prevention efforts. From 2013 to 2023, a total of 11,26,878 persons were prescribed oral or injectable PrEP.

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

How Was It Studied for the Prevention of HIV? Two large studies were conducted to see if Apretude is safe and effective as a PrEP regimen in people at risk of getting HIV. In both studies ...

HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...

Given recent approvals and a promising pipeline, new biomedical HIV prevention tools for women have the potential to ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...